Company news

Jiangsu Cowin Biotech Co., Ltd. Class A (SSE:688426) news

Jiangsu Cowin Biotech Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "JIANGSU COWIN BIOTECH CO., LTD."Announcement on the Board Secretary's…

Jiangsu Cowin Biotech Co., Ltd. Class A (SSE:688426) news

Press releases & updates

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on the Board Secretary's Receipt of the Qualification Training Certificate and Official Assumption of Duties

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Initial Grant of Restricted Shares to Participants under 2026 Restricted Share Incentive Plan

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Class III Medical Device Registration Certificate for the Clostridium difficile tpi and Toxin A, Toxin B Gene Detection Kit (Fluorescent PCR Method)

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Resignation of Director, Deputy General Manager and Board Secretary and Appointment of New Board Secretary

"JIANGSU COWIN BIOTECH CO., LTD."Self-inspection Report on Trading in the Company's Shares by Insiders in Relation to 2026 Restricted Share Incentive Plan

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Resolutions of the 23rd Meeting of the 2nd Board of Directors

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Resolutions of the 24th Meeting of the 2nd Board of Directors

"JIANGSU COWIN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Mycoplasma Pneumoniae Nucleic Acid and Drug-resistant Mutation Site Detection Kit (Fluorescent PCR Method)

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Announcement on Using Partial Extra Raised Funds to Permanently Supplement Current Capital

Announcement on Voluntary Disclosure of Obtaining the Class III Medical Device Registration Certificate for the Clostridioides difficile Glutamate Dehydrogenase Antigen and Toxin Detection Kit (Enzyme-Linked Immunochromatographic Assay)

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of the Receipt of Class III Medical Device Registration Certificates for Six Respiratory Pathogen Nucleic Acid Detection Kits (Fluorescent PCR Method)

Announcement on Result of Some Directors and Senior Management Members Failing to Reduce Shareholding upon Expiration of the Lock-up Period

Report for Q1 2026

Announcement on Making Provisions for Asset Impairment for 2025

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Voluntary Disclosure of the Receipt of Class III Medical Device Registration Certificates for Nine Respiratory Pathogen Nucleic Acid Detection Kits (Fluorescent PCR Method)

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Change of Sponsor Representative for Continuous Supervision

Announcement on Retirement and Resignation of Internal Audit Heads

Announcement on Expected Loss in Performance for 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Shareholding Reduction Plan of Partial Directors and Senior Management Members

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Listing and Circulation of Shares Subject to Lock-up Released from Stock Option Exercises Granted Prior to the Initial Public Offering

Report for Q3 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Notice on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Cancellation of Some Special Accounts for Raised Funds

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Announcement on Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital

Announcement on Resignation of Non-independent Director and Election of Employee Representative Director

Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors

Announcement on Reply to Supervision and Inquiry Letter Regarding Information Disclosure of 2024 Annual Report

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Voluntary Disclosure of Participating in the Establishment of Venture Capital Fund and Signing Partnership Agreement

2024 Annual Report

Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Human Septin9, SDC2, and NDRG4 Gene Methylation Detection Kit

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Implementation Results of Share Repurchase and Share Changes

Announcement on Progress in Repurchasing Shares through Call Auction

Announcement on Expected Loss in Annual Performance for 2024

Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Detection Kit

Announcement on Resignation of Deputy General Manager and Chief Financial Officer

Announcement on Resolution of the 3rd Extraordinary General Meeting in 2024

Announcement on Cancellation of Share Options Not Exercised at the End of the 2nd Exercise Period and Failing to Meet Exercise Conditions in the 3rd Exercise Period of the 2021 Stock Option Incentive Plan

Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Helicobacter Pylori Resistance Gene Test Kit